The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Barriers to implementing expanded access programs in oncology: A multidisciplinary perspective.
 
Sherry Fu
Employment - Aetio Biotherapy
Leadership - Aetio Biotherapy
Stock and Other Ownership Interests - Aetio Biotherapy
Patents, Royalties, Other Intellectual Property - Compositions and methods for treating viral infections
 
Maishara Muquith
No Relationships to Disclose
 
Erin Fenske Williams
Consulting or Advisory Role - Genentech/Roche; Lilly; Syneos Health
 
Larry D. Anderson, Jr
Honoraria - Abbvie; Amgen; BeiGene; Bristol-Myers Squibb/Celgene; Cellectar; GlaxoSmithKline; janssen; Karyopharm Therapeutics; Oncopeptides; Prothena
Consulting or Advisory Role - Abbvie; amgen; BeiGene; Bristol-Myers Squibb/Celgene; Cellectar; GlaxoSmithKline; janssen; Karyopharm Therapeutics; Oncopeptides; Prothena
Research Funding - amgen; bms; celgene; GlaxoSmithKline; janssen; Karyopharm Therapeutics
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Aptitude Health; Clinical Care Options; Curio Science; MJH Life Sciences; Pacific Genuity; Peerview
Consulting or Advisory Role - Aravive; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Eisai; Exelixis; Janssen; Lilly; Merck; Pfizer; QED Therapeutics; Sanofi/Aventis; Seagen
Research Funding - Astellas Pharma; Janssen (Inst); Loxo/Lilly (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OmniSeq (Inst); Pfizer (Inst); Regeneron (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Janssen
 
Shaalan Beg
Employment - Science 37
Consulting or Advisory Role - Cancer Commons; Foundation Medicine; Genmab/Seagen; Ipsen
Speakers' Bureau - Sirtex Medical
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Delfi Diagnostics (Inst); ImmuneSensor Therapeutics (I); Merck (Inst); Merck Serono (Inst); Tolero Pharmaceuticals (Inst)